Semaglutide (Ozempic, Wegovy, Rybelsus)
Semaglutide (NNC 0113-0217; N-u26-[2-(2-{2-[2-(2-{2-[(S)-2-carboxy-3-({2-[2-(3-{(S)-3-carboxy-3-[(18-carboxy-1-oxooctadecyl)amino]propanoyl}amino)ethoxy]ethoxy}acetyl)amino]-3-hydroxypropanoyl}amino)ethoxy]ethoxy}acetyl)-[Aib8,Arg34]-GLP-1(7-37)-peptide])
Approved status applies to specific products, routes, and indications, not every use context discussed online.
An FDA-approved medication sold as Ozempic (for type 2 diabetes) and Wegovy (for weight management), given as a once-weekly injection or a daily oral tablet (Rybelsus). It mimics a natural gut hormone that controls blood sugar and appetite, and a major clinical trial showed it also significantly reduces the risk of heart attack and stroke.
Safety Summary
Gastrointestinal adverse events (nausea, vomiting, diarrhea) are the primary dose-limiting toxicities and the main reason for dose adjustment or discontinuation. These are typically most pronounced during initiation and dose escalation and tend to decrease over time. Slow titration is the primary strategy for improving tolerability. Hypoglycemia risk is increased when co-administered with insulin or sulfonylureas. Psychiatric events (depression, anxiety, suicidal ideation) are under FDA monitoring but no causal link confirmed as of Jan 2026. Rodent thyroid C-cell tumors underpin a boxed warning (class effect for GLP-1 RAs) but no clear human signal to date. Weight regain occurs upon discontinuation (STEP 1 extension data). Anti-semaglutide antibody formation is uncommon (low single-digit %) and predominantly non-neutralizing.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-7]